CC chemokine receptor 5 (CCR5) is a G-protein-coupled
HIV-1 entry into target cells requires sequential interactions of the surface subunit (gp120) of the viral envelope glycoprotein with cell surface CD4 and a G-protein-coupled receptor (GPCR) 3 acting as a coreceptor, namely either CC chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4) (1) (2) (3) (4) . The role of CCR5 as a HIV coreceptor was originally suggested after the identification that the CCR5 chemokines macrophage inflammatory protein 1␣ (MIP1␣)/ CCL3, MIP1␤/CCL4, and regulated upon activation, normal T-cell expressed and secreted (RANTES)/CCL5 act as HIVsuppressive factors (5, 6) . CCR5-using viruses (R5 viruses) are predominantly transmitted and persist throughout infection, whereas variants that use CXCR4 (X4 or R5/X4 viruses) emerge late in infection in a number of infected individuals (7) . Additionally, individuals carrying the CCR5 ⌬32 allele, which results in reduced receptor expression at the cell surface, resist infection without any obvious harmful effects on health (8) . In view of these data, much research effort has been devoted to develop CCR5 ligands with antiviral properties, including chemically modified chemokines (9, 10), monoclonal antibodies (11, 12) , and in more recent years a new class of nonpeptidic, low molecular weight compounds with potential for oral availability. Members of this latter class of molecules include vicriviroc (SCH-D, SCH 417690), which is currently under late phase clinical trials (13) , and maraviroc (UK-427857, marketed as Selzentry or Celsentry (Pfizer) and hereafter referred as MVC), which recently received approval for use in the treatment of patients harboring only R5 viruses (14 -16) . Nonpeptidic small CCR5 ligands prevent gp120 from binding to CCR5 and inhibit HIV entry, but the molecular mechanisms by which they act as antiviral molecules remain incompletely solved. These entry inhibitors lack agonist activity, and as such do not promote CCR5 internalization, and antagonize signaling and endocytosis of the receptor mediated by chemokines (17) (18) (19) (20) (21) . Mutational studies and molecular modeling have proposed that these molecules do not interact with the regions of CCR5 involved in the binding of gp120 and chemokines, particularly the N-terminal domain and the second extracellular loop (ECL2) (22, 23) , but lodge in a hydrophobic cavity located between the transmembrane domains of the receptor (24 -28) , thus suggesting that these molecules mediate their inhibitory effects on gp120 binding and chemokine functions by an allosteric mechanism, i.e. by inducing conformational changes of CCR5. Further supporting the allosteric nature of these molecules are data showing that they can in-duce differential alterations of distinct receptor functions (18, 19, 21) . In other words, members of this class of molecules prevent some receptor functions but not others. This has clearly been highlighted for aplaviroc, which permits simultaneous binding of CCL5 to CCR5 and CCL5-mediated chemotaxis and receptor endocytosis (18, 21) , but fully suppresses CCL5-mediated intracellular calcium release. In contrast to CCL5, aplaviroc blocks the binding of other chemokines to CCR5, thus indicating that this inhibitor is probe-dependent, which is considered a characteristic feature of allosteric modulators (19, 21) . In line with this, small molecule CCR5 inhibitors have been found to alter differently the binding of different monoclonal antibodies to the receptor (18) .
As compared with chemokines, allosteric interactions between gp120 and the small molecule CCR5 inhibitors have not been formally demonstrated. Also, data remain scarce on which CCR5 conformations, to which gp120 would not bind, are induced by these inhibitors. We and others have previously demonstrated that some of these molecules behave as inverse agonists for CCR5, thus suggesting that they stabilize CCR5 in inactive conformations that are uncoupled from Gproteins (29, 30) , but whether or not all members of this class of molecules share this property is not well documented. In fact, viruses showing resistance to some inhibitors retain susceptibility to others (31) , thus suggesting that, although all of these molecules locate in the same binding pocket, their effects on CCR5 conformation differ to some extent. Inverse agonism might take part in inhibitor-mediated blocking of chemokine binding to CCR5, as suggested by a recent work showing that coupling to G-proteins is necessary for CCR5 to bind CCL4 with high affinity (32) . To what extent inverse agonism at CCR5 could also alter gp120 binding and/or other entry-associated events and thus contribute to antiviral activity is not known. However, gp120-mediated intracellular signaling through CCR5 has been reported (33) (34) (35) , thus opening the possibility that G-proteins coupled to CCR5 may play a role in gp120 binding to the receptor and more generally in HIV infection.
In this study, we have investigated the mechanisms whereby TAK779, which was the first small molecule CCR5 inhibitor to be described (17) , and MVC exert their antiviral activity. Radioligand dissociation and displacement binding assays demonstrated that the inhibitors produce an allosteric inhibition of gp120 and chemokine binding to CCR5. Interestingly, those inhibitors showed inverse agonism, whose relative efficacy correlated with their capacity to dissociate gp120 from CCR5 but not with their antiviral potency, thus making it likely that allosteric blocking of HIV-1 infection by small molecule CCR5 inhibitors does not rely only on their ability to decrease affinity of gp120 for CCR5. Human peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy blood donors and were purified by centrifugation through a Ficoll-Hypaque density gradient (Pharmacia Corp., Peapack, NJ). PBMCs were maintained for 2 days in RPMI 1640 medium containing IL-2 (300 IU/ml) and phytohemagglutinin (5 g/ml), and then for additional 5 days in the presence of IL-2 alone. HEK 293T or U87 cells expressing CCR5 and/or CD4 were cultured in DMEM (Invitrogen) supplemented with 10% FCS, 2 mM L-glutamine, 100 g/ml streptomycin, and 100 units/ml penicillin. The WT-CCR5-and R126N-CCR5-expressing HEK 293T cells used in this study were described previously (30) . Transient expression of CD4 in CCR5-expressing HEK 293T cells was performed using the calcium phosphate-DNA coprecipitation method of transfection.
EXPERIMENTAL PROCEDURES

Production of Soluble Monomeric [
35 S]gp120-The gp120 coding sequence from the R5-tropic, HIV-1 primary strain Bx08 was subcloned from plasmid p133. 3 (36) into the Semliki forest virus-derived expression vector pSFV2 (37) . Recombinant defective Semliki forest virus particles (SFVgp120 Bx08 ) were produced as described previously (38) . Soluble gp120 was produced by infection of baby hamster kidney cells by SFVgp120 Bx08 . At 6 h post-infection, culture medium (BHK-21 Glasgow's modified Eagle's medium with 5% FCS, 1% penicillin/streptomycin, 20 mM HEPES, and 10% tryptose phosphate broth) was replaced by 0% FCS methionine/cysteine-free DMEM (ICN Biochemicals) prior to addition of 200 Ci/ml [ 35 S]cysteine and -methionine (EasyTag Express 35 S, PerkinElmer Life Sciences). Synthesis of soluble, monomeric 35 S-labeled gp120 was continued up to 24 h post-infection. The culture medium was then clarified and concentrated using a VivaSpin 20 column (30-kDa molecular mass cutoff, Sartorius) prior to dialysis against PBS. [ 35 S]gp120 concentration was determined by Western blot analysis using gp140 MN/Lai as a standard and the mouse anti-gp120 (V3) mAb K24 (38) .
Membrane Preparation-Crude membranes from parental, WT-, or R126N-CCR5-expressing HEK 293T cells were prepared as described previously (30) . Briefly, cells were incubated for 30 min at 4°C in buffer A (15 mM Tris-HCl, pH 7.5, 2 mM MgCl 2 , 0.3 mM EDTA, and 1 mM EGTA), disrupted using a Dounce homogenizer (Kontes), and centrifuged at 500 ϫ g for 5 min at 4°C. Postnuclear supernatants were ultracentrifuged at 40,000 ϫ g for 30 min at 4°C. Membrane pellets were washed once in buffer A, before being resuspended in buffer B (75 mM Tris-HCl, pH 7.5, 12.5 mM MgCl 2 , 0.3 mM EDTA, 1 mM EGTA, 250 mM sucrose). Membrane aliquots at a protein concentration o fϾ1 mg/ml were stored at Ϫ80°C until use.
[ 35 
S]GTP␥S Binding-[
35 S]GTP␥S binding to membranes from WT-or R126N-CCR5-expressing HEK 293T cells was performed as described previously (30) . Briefly, membranes (10 -15 g of proteins/well) were incubated for 15 min at 30°C in assay buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 g/ml saponin, 0. , which was present at the initiation of the dissociation kinetics, represented 15 or 6%, respectively, of the amount of radioligand engaged initially. Results are expressed as the ratio between the amount of radioligand bound to membranes at the indicated dissociation time (B t ) and that bound to membranes at time 0 (B 0 ). Data were analyzed with the Prism software using monophasic or biphasic exponential decay functions. One-phase and two-phase exponential decay models were compared using an F test.
Viral Clones and Infection Inhibition Assays-The pBx08Ren plasmid was generated by cloning from plasmid p133.3 (36) gp160 of the Bx08 strain in place of the NL4-3 envelope in the previously described plasmid pNL4-3Ren (40) . The pJRRen plasmid, which contains gp160 from the JR-CSF HIV-1 strain, was described previously (41) . Renilla luciferase reporter viruses were prepared by transfecting the pBx08Ren or the pJRRen plasmid in HEK 293T cells using the calcium phosphate-DNA coprecipitation method. Forty eight hours post-transfection, cell culture supernatants were harvested, clarified by centrifugation at 500 ϫ g for 5 min, and frozen at Ϫ80°C. The amount of p24 antigen in the supernatants was quantified using a commercially available ELISA kit (Innotest HIV antigen mAb; Innogenetics, Gent, Belgium). Drug susceptibility assays were carried out as described previously (40) . Briefly, CCR5-and CD4-expressing HEK 293T or U87 cells were plated onto flat-bottom 96-well plates (2 ϫ 10 4 cells/well) and incubated overnight at 37°C under 5% CO 2 . Regarding PBMCs, 1 ϫ 10 5 cells/well were dispensed in round-bottom 96-well microtiter culture plates in the presence of IL-2 (300 IU/ml). TAK779 or MVC, serially diluted in PBS, was then added to the cells for 4 h at 37°C under 5% CO 2 , before the cells were infected with equal amounts of viruses as assessed by p24 measurement. At 48 h post-infection, cells were lysed, and viral replication was assessed by measuring luciferase activity (Renilla Luciferase Assay, Promega, Madison, WI) using a 96-well plate luminometer "Orion" (Berthold, Oak Ridge, TN). The inhibition percentage was calculated as (1 Ϫ(luciferase activity in the presence of drug/luciferase activity in the absence of drug)) ϫ 100. IC 50 values were calculated with the Prism software using a nonlinear regression model. Fig. 1d ). This finding strongly suggests that for each of the two radioligands, high affinity binding either to membranes or to intact cells is mediated by a same fraction of receptors.
RESULTS
Formation of active receptor conformational states with high affinity for agonists is recognized to be promoted by receptor coupling to nucleotide-free G-proteins (45, 46) . Therefore, we repeated the binding experiments with crude membranes in the presence of Gpp(NH)p, a nonhydrolysable GTP analog that binds to ␣-subunits of activated G-proteins and then uncouples receptors permanently from G-proteins. As shown in Fig. 1e , Gpp(NH)p strongly decreased [
125 I]CCL3 binding to CCR5, thus confirming previous results showing that G-protein coupling is needed for high affinity binding of chemokines to the receptor (32) . In striking contrast, [ 35 S]gp120 binding was unaffected by Gpp(NH)p, thus indicating that the viral envelope binds to CCR5 independently of the receptor coupling to G-proteins. We obtained similar results in intact cells that were pretreated overnight with pertussis toxin at 100 ng/ml (Fig. 1e) . To further confirm these findings, we performed competitive binding experiments in which binding of [ 35 S]gp120 to CCR5-expressing membranes was measured in the presence of increasing concentrations of the unlabeled CCR5 agonist MIP1␤/CCL4 (Fig. 1f) . Displacement of [ 35 S]gp120 binding by CCL4 gave rise to a biphasic curve, thus indicating the presence of two distinct classes of [ 35 S]gp120 binding receptors with high (K i ϭ 1.2 Ϯ 0.6 nM) and low (K i ϭ 224 Ϯ 120 nM) affinities for the chemokine. Receptors of high affinity for CCL4 represented 38 Ϯ 5% of total gp120-binding sites. Addition of Gpp(NH)p resulted in a monophasic curve representing the low affinity state (K i ϭ 86 Ϯ 11 nM). Altogether, these results indicate that high affinity binding of chemokines requires CCR5 coupling to G-proteins, whereas gp120 most probably binds equally well to both G-protein-uncoupled and -coupled receptors and to this regard behaves as a neutral antagonist for CCR5.
TAK779 and MVC Are Inverse Agonists for CCR5 That Stabilize Different Receptor Conformations-Using a [
35 S]GTP␥S binding-based assay, we found that stimulation of CCR5 by CCL4 led to a dose-dependent activation of G-proteins (Fig.  2a) . As we demonstrated previously (30) , basal [ 35 S]GTP␥S binding to CCR5-expressing membranes was also increased, compared with that to membranes from parental cells (data not shown) or cells expressing the R126N-CCR5 mutant receptor, which is defective in its ability to activate G-proteins (Fig. 2, a and b) (data not shown). This indicates that a fraction of CCR5 converts spontaneously from inactive to active conformations and constitutively activates G-proteins even in the absence of agonist. Exposure of CCR5-expressing membranes to TAK779 resulted in a dose-dependent decrease in basal [ 35 S]GTP␥S binding (Fig. 2b) . At high concentrations of TAK779, constitutive activity of CCR5 was no longer apparent, thus indicating that TAK779 is a full inverse agonist for CCR5. MVC also reduced basal [ 35 S]GTP␥S binding to CCR5-expressing membranes, but less efficiently than TAK779. Indeed, even at the highest concentrations, MVC only weakly inhibits constitutive activity of CCR5, thus indicating that MVC acts as a partial inverse agonist for CCR5. Together, the results suggest that TAK779 and MVC stabilize distinct conformations of CCR5, which exhibit different abilities to activate G-proteins. In particular, TAK779 would be much more effective than MVC at stabilizing the G-proteinuncoupled inactive states of CCR5.
We therefore hypothesized that TAK779, and perhaps to a lesser extent MVC, might display increased affinity for Gprotein-uncoupled receptors. To directly address this issue, we performed competition experiments between [
125 I]CCL3 and increasing concentrations of either MVC or TAK779, in Collectively, these results are consistent with the idea that the full inverse agonist TAK779 binds preferentially to, and thus stabilizes, G-protein-uncoupled inactive conformations of CCR5. In contrast, binding of MVC seems to be less sensitive to receptor coupling to G-proteins, thus explaining why this molecule behaves as a weak inverse agonist for CCR5.
TAK779 and MVC Enhance Dissociation of [
125 I]CCL3 from CCR5-We next investigated the molecular mechanisms by which TAK779 and MVC inhibit [
125 I]CCL3 binding to CCR5-expressing membranes. In particular, we asked whether inverse agonism of each of these molecules contributes to binding inhibition of the chemokine. Allosteric compounds have been characterized by their ability to change the dissociation rate of orthosteric radioligands from receptors (48) . For those experiments, dissociation could be initiated either by extensive (also termed "infinite") dilution of the radioligand or by addition of an excess of unlabeled competitive ligands, such that minimal reassociation of the dissociated radioligand occurs. We studied the effects of TAK779 and MVC on the rate of dissociation of [
125 I]CCL3 from CCR5 by the method of infinite dilution (Fig. 3) . We first allowed 125 I]CCL3 that remained bound to CCR5 was counted at different time points (Fig. 3a) . We found that infinite dilution of [ 125 I]CCL3 accelerated dissociation of the chemokine from CCR5, as compared with that measured after dilution in a smaller volume of buffer in which dissociated [
125 I]CCL3 could reassociate to free CCR5. Addition in the dissociation buffer of an excess concentration of a competitive ligand such as the anti-CCR5 mAb 45531 that binds to ECL2 of CCR5 did not change the dissociation rate of [ 125 I]CCL3, thus indicating that the conditions of infinite dilution was fulfilled and that the maximal dissociation rate of the chemokine was achieved under these conditions.
We found that dissociation of [ 125 I]CCL3 was best described by a two-phase exponential decay function, thus revealing that a proportion of the chemokine was dissociated rapidly (k off fast ϭ 2.8 Ϯ 0.1 h Ϫ1 ), whereas the rest was dissociated with a slower rate (k off slow ϭ 0.23 Ϯ 0.02 h Ϫ1 ). The ratio k off slow /K D yielded a k on value of 1.6 ϫ 10
M
Ϫ1 .s Ϫ1 , which is within the range of on-rate constant values for peptide-receptor interactions (49) . Addition of Gpp(NH)p in the dissociation buffer enhanced the dissociation rate of [ 125 I]CCL3 from CCR5 (Fig. 3b) , as mentioned previously (32) , suggesting that fast dissociating [
125 I]CCL3 represents the fraction of chemokines that dissociated from G-protein-uncoupled receptors, which are in an agonist low affinity state. Accordingly, addi- tion of TAK779 at 1 M in the dissociation buffer also enhanced the proportion of chemokines dissociating rapidly. The dissociation rate of [ 125 I]CCL3 was increased in the presence of MVC too, although to a lower extent than with TAK779. Therefore, both inhibitors decoupled [ 125 I]CCL3 from CCR5 with an efficiency that correlated with their inverse agonist efficacy, thus suggesting that stabilization of G-protein-uncoupled receptors contributes to dissociation of the chemokine.
TAK779 and MVC Inhibit gp120 Binding to CCR5 by a Noncompetitive Mechanism-We next addressed the issue of the mechanisms by which TAK779 and MVC inhibit HIV entry into cells. For that purpose, we first performed competition experiments in which binding of [ 35 S]gp120 was measured in the presence of increasing concentrations of either TAK779 or MVC (Fig. 4a) . In contrast to what we observed using [ 125 I]CCL3 as a radioactive tracer, we found that TAK779 and gp120 competed for binding to a single class of receptors, whose apparent affinity (IC 50 ϭ 22 Ϯ 9 nM) for the inhibitor was not modified by Gpp(NH)p. This further confirms that gp120-bound receptors are primarily uncoupled from G-proteins. The same pattern was observed for the binding of MVC. The IC 50 values obtained with MVC were slightly lower than those of TAK779 (IC 50 ϭ 6.4 Ϯ 3 nM), thus suggesting that MVC binds more efficiently to gp120-binding receptors than TAK779.
We next performed competition experiments with TAK779 or MVC using increasing concentrations of [ 35 S]gp120-sCD4 complexes from 5 to 50 nM (Fig. 4, b and c) . Indeed, it has been reported that the relationship between the observed IC 50 value and the concentration of radioactive tracer in displacement experiments can inform whether the inhibition of binding is competitive (i.e. displaceable) or noncompetitive (21) . The IC 50 value is expected to increase linearly with the radioligand concentration for competitive inhibition, whereas an unchanged IC 50 value may indicate that noncompetitive inhibition occurs and, if so, is an estimate of the equilibrium dissociation constant value of the inhibitor-receptor complex (21) . We found that the IC 50 values do not change with increases of the concentration of radioactive gp120 (Fig. 4d) S]gp120, thus further supporting the conclusion that binding of gp120 to CCR5 is independent of G-proteins (supplemental Fig. S2 ). Dissociation of [
35 S]gp120 that was measured in the presence of excess unlabeled gp120 and sCD4 was monophasic (i.e. dissociation fitted closely to a straight line when represented on a logarithmic scale, see Fig. 5a ), thus indicating that the protein dissociates from a homogeneous population of receptors at its maximal unchanging rate (k off ϭ 0.46 Ϯ 0.06 h Dissociation experiments were then repeated following a 80-fold dilution of [ 35 S]gp120 in buffer alone or containing concentrations ranging from 0.3 to 100 M of either TAK779 (Fig. 5b) or MVC (Fig. 5c) . In buffer alone, [ 35 S]gp120 dissociated from CCR5 more slowly than in the presence of excess unlabeled gp120 (i.e. bold dotted line in Fig. 5, a-c could reassociate with free CCR5 because of insufficient dilution. However, we consistently observed that [ 35 S]gp120 dissociated at a faster rate in the presence of either of the two CCR5 inhibitors than in the presence of excess unlabeled gp120, thus indicating that TAK779 and MVC promoted dissociation of the viral envelope from CCR5 by allosteric mechanisms. It should be noted that the inhibitors at moderate concentrations accelerated dissociation of [ 35 S]gp120 in a dose-dependent manner (Fig. 5d) (Fig. 5d) , which might indicate that the ability of both inhibitors to dissociate [ 35 S]gp120 from CCR5 correlates with their efficacy as inverse agonists for the receptor. In further support of this possibility, at the highest concentrations of inhibitors, the apparent rate constants for [ 35 S]gp120 dissociation approached a limiting value that was higher for TAK779 (k off TAK779 ϭ 7.2 Ϯ 0.8 h
Ϫ1
) than for MVC (k off MVC ϭ 2.4 Ϯ 0.4 h Ϫ1 ) (Fig. 5d ). This suggests that at high concentrations of inhibitors, the dissociation rate of [ 35 S]gp120 does not depend any longer on the association rate of inhibitors to CCR5, but it more likely reflects dissociation of the glycoprotein from inhibitor-bound receptors. Considered as a whole, the results thus strongly suggest that gp120 dissociates more rapidly from TAK779-bound CCR5 than from MVC-bound CCR5.
Inhibition of HIV Infection by TAK779 and MVC-We directly compared the two inhibitors in their ability to prevent HIV-1 entry and replication. For that purpose, NL4-3-based viruses containing the envelope glycoprotein of the HIV-1 isolate Bx08 and Renilla luciferase as a reporter gene were used to infect CD4-and CCR5-expressing U87 or HEK 293T cells or activated PBMCs in the presence of serial dilutions of either TAK779 or MVC (Fig. 6, a-c, and Table 1 ). To quantify virus replication, target cells were lysed and luciferase activity was measured 48 h post-infection. We found that MVC was consistently more than 2 orders of magnitude more potent than TAK779 for inhibiting infection of all of three cell types used. Similar results were observed using the envelope glycoprotein of the R5-tropic HIV-1 strain JR-CSF instead of that of the Bx08 strain (Fig. 6, d-f , and Table 1 ), thus making it unlikely that the differential ability of MVC and TAK779 to inhibit infection depends merely on the envelope glycoprotein used. Half-maximal inhibitory concentration (IC 50 ) values for MVC were in the nanomolar range in U87-and PBMC-based assays, in accordance with an earlier work (14) , but dramatically increased in the experiments with the CD4-and CCR5-expressing HEK 293T cells. A similar trend has been observed for TAK779 as well, which may be due to the fact that HEK 293T cells express substantially higher amounts of CCR5, as compared with U87 cells and PBMCs (see Table 1 ). Indeed, previous reports highlighted that increasing the CCR5 expression level at the cell surface decreases the antiviral potency of small molecule CCR5 inhibitors (51, 52) . High amounts of CCR5 in HEK 293T cells might suggest that these cells contain more receptors than G-proteins, as compared with the other cell types. However, as shown here (Fig. 2c) , TAK779 and to a lesser extent MVC bind preferentially to G-proteinuncoupled receptors, thus making it unlikely that the occurrence of "spare" receptors explains why infection of HEK 293T cells is less sensitive to entry inhibitors. Nevertheless, the two-log difference in the IC 50 values between MVC and TAK779 is apparent in each of the cells used and is thus unlikely to be dependent upon receptor expression levels. The 100-fold weaker antiviral activity of TAK779, as compared with MVC, cannot be explained by our results showing that both inhibitors have affinities for the gp120-binding receptors that are in the same range (Fig. 4) and contrasts with the increased ability of TAK779 to promote gp120 dissociation from CCR5 (Fig. 5) . This strongly suggests that the antiviral activity of these small molecule CCR5 inhibitors might not rely only on their ability to interfere with gp120 binding to the coreceptor.
DISCUSSION
TAK779 and MVC Are Inverse Agonists for CCR5, which Stabilize Distinct Receptor Conformations-CCR5 like other
GPCRs can convert spontaneously from inactive to active conformations (30, 53, 54) . We found that basal activity of CCR5 was reversed to different extents by TAK779 and MVC, thus identifying both molecules as inverse agonists for the receptor. These molecules are thought to bind to a conserved hydrophobic cavity formed by the upper half of the transmembrane helices (24 -26) , some of which contain amino acids previously found to be important structural determinants for activation of the receptor (55, 56) . So, direct or indirect interactions with these residues could explain how these, and others (29, 57) , small molecule CCR5 inhibitors prevent the receptor from spontaneous activation. The full inverse agonist activity of TAK779 we documented in this study is likely to rely on its ability to bind preferentially to and to stabilize G-protein-uncoupled, inactive conformations of CCR5. This assumption is in particular supported by our finding that disrupting CCR5 coupling to G-proteins by Gpp(NH)p improves the efficiency with which TAK779 competes with the chemokine [ 125 I]CCL3 for binding to the receptor (Fig. 2c) . Preferential binding of TAK779 to inactive receptors is also consistent with the recent observation that inverse agonists act by preventing formation of active conformations rather than by destabilizing preformed receptor-G-protein complexes (46) . In contrast to TAK779-occupied receptors, those that have bound the partial inverse agonist MVC maintain constitutive coupling to G-proteins to some extent, thus indicating that TAK779 and MVC stabilize different conformations of CCR5. This may explain why some viruses that are resistant to MVC retain susceptibility to TAK779 (31, 58) . Furthermore, given that CCR5 exists in multiple conformations displaying distinct functional properties (23, 59) , our results raise the possibility that these conformations differ in their capacity to bind TAK779 or MVC.
The stabilization of different CCR5 conformations by TAK779 and MVC can be explained by specific binding modes. Although both molecules locate in the transmembrane domains of the receptor, they occupy overlapping but distinct regions of the transmembrane cavity and interact with different sets of residues (24 -26) . For example, whereas replacement of Tyr-37 by alanine has been described to impair TAK779 binding to CCR5 (24), we observed that this mutation actually preserves MVC binding. 4 Interestingly, replacement of Tyr-37 by alanine also suppresses chemokine binding to CCR5, but only moderately affects that of gp120 (26) , thus suggesting that Tyr-37 is mandatory for maintaining CCR5 in a high affinity conformation for agonists. It is tempting to speculate that CCR5 coupling to G-proteins, which provides high affinity binding of chemokines (Fig. 1e ) (32) and is disrupted by TAK779 binding (Fig. 2b) , might play a role in this process. As another example, in contrast to TAK779, MVC binding to CCR5 involves the receptor helix 5. The replacement of Ile-198 by an alanine results in a 100-fold decrease in the binding affinity of MVC for CCR5, although it has little effect on that of TAK779 (25, 26) . 4 Of note, although the I198A substitution preserves binding of both chemokines and gp120 (25, 26) , 4 it dramatically impairs HIV-1 infection (26). These observations are in keeping with the 100-fold higher antiviral potency shown by MVC, as compared with TAK779 (Fig. 6) , even though both inhibitors compete for [ 35 S]gp120 binding to CCR5 with nearly similar potencies (Fig. 4) . This strongly suggests that inhibition of HIV-1 infection by MVC or by the I198A substitution involves a mechanism other than inhibition of gp120 binding to CCR5. (Fig. 4) 35 S]gp120-occupied CCR5, and then change the receptor conformation in such a way that the glycoprotein is released from the receptor. These results thus imply that both inhibitors bind to regions of CCR5 separate from the gp120-and CCL3-binding sites. Alternatively, but not exclusively, it cannot be excluded that allosteric interactions between the entry inhibitors and gp120 or CCL3 might also transmit across CCR5 oligomers. Indeed, recent data support the notion that GPCRs, including CCR5, form homoand heterooligomers and that negative binding cooperativity can occur between the associated receptors (32, 60) . Overall, these results clarify why resistance to CCR5 inhibitors was found to result in incomplete inhibition of infection at saturating inhibitor concentration, i.e. the maximum percent inhibition plateaus at a value lower than 100%, whereas resistance to competitive inhibitors is manifested, instead, by increased IC 50 values for the inhibitors (61) . The decrease in the maximum percent inhibition values is suggestive of viruses having acquired the ability to use inhibitor-bound receptors in addition to the free receptors (31, 52) , which is consistent with our present results showing that gp120 and members of this class of molecules bind to separate domains of CCR5.
Mechanisms (Fig. 3b) , suggesting that CCR5 uncoupling from G-proteins is a mechanism by which TAK779 and MVC allosterically interfere with the binding of the chemokine to the receptor. In contrast to CCL3, however, dissociation of [ 35 S]gp120 did not depend on the receptor coupling to G-proteins, indicating that the ability whereby TAK779 and MVC promote dissociation of [ 35 S]gp120 from CCR5 does not stem from their inverse agonist activity. Among the mechanisms involved, it could be envisaged that TAK779 and MVC might act on gp120 binding by changing the conformation of ECL2. In support of this assumption, we have observed that both inhibitors interfere with the binding of the anti-CCR5 mAb 45531 to the distal half of ECL2 (but not with the binding of the anti-CCR5 mAbs 2D7 and CTC5 to the proximal half of ECL2 and the receptor N-terminal tail, respectively). These findings are in fact fully consistent with recent structural data on related CCR5 inhibitors indicating that their binding to the receptor disrupts interhelix interactions and interactions between helices and ECL2 (27) .
gp120 Is a Neutral Antagonist for CCR5-Lack of effect of Gpp(NH)p on dissociation of [ 35 S]gp120 from CCR5 is consistent with our result in Fig. 1 showing that, in contrast to CCL3, high affinity binding of gp120 to CCR5 does not depend on the receptor coupling to G-proteins. Altogether, these results identify the viral glycoprotein as a neutral antagonist for CCR5. It should be noted that this conclusion does not formally rule out the possibility that gp120 may induce signaling events when interacting with CCR5, as documented by previous studies (62) . Indeed, like for other GPCRs (63) , it is reported that CCR5 signaling includes G-protein-independent signaling pathways, including those of the JAK/STAT and ␤-arrestin proteins (64) , which might be activated in response to gp120. Consistent with this assumption, studies have emphasized that R5-tropic gp120-induced intracellular signals through CCR5 are not sensitive to pertussis toxin, thus indicating that they are not dependent upon G␣ i/o proteins (33) (34) (35) . It could be hypothesized that gp120 might act as a "biased" agonist activating some signaling pathways but not others, as it has been reported for other GPCR ligands (65) .
Antiviral Activity of TAK779 and MVC Does Not Correlate with Their Ability to Interfere with gp120 Binding to CCR5-
Although CCR5 coupling to G-proteins and interaction with gp120 are two processes that were demonstrated here not to be dependent upon each other, the magnitude with which these processes are altered by both inhibitors varies in the same way. Indeed, it could be deduced from our results that gp120 from the Bx08 HIV-1 strain is dissociated from TAK779-bound CCR5 and MVC-bound CCR5 15-fold (k off TAK779 ϭ 7.2 Ϯ 0.8 h
Ϫ1
) and 5-fold (k off MVC ϭ 2.4 Ϯ 0.4 h Ϫ1 ) more rapidly, respectively, than from the free receptor (k off ϭ 0.49 Ϯ 0.06 h Ϫ1 ). The fact that gp120 is detached from CCR5 more readily in the presence of TAK779 than in the presence of MVC might be accounted for by gp120 having a lower affinity for TAK779-than for MVC-bound CCR5. It should be noted, however, that our results from the competition experiments in Fig. 4 do not follow the same trend, as TAK779 is almost 3-fold less potent than MVC for competing for binding of [ 35 S]gp120 to CCR5 (IC 50 ϭ 22 Ϯ 9 and 6.4 Ϯ 3 nM for TAK779 and MVC, respectively). These discrepancies can be explained by the fact that MVC exhibits a more prolonged receptor occupancy than TAK779 (k off ϭ 0.0036 versus 0.013 h Ϫ1 (21)). As explained above, the IC 50 values for both inhibitors that have been deduced from the [ 35 S]gp120 displacement binding experiments can be considered as estimates of their equilibrium dissociation constants for the receptor. So, the data from these experiments indicate that the affinities of MVC and TAK779 for the gp120 binding receptors are in almost the same range of magnitude. Yet, we have observed that TAK779 is more than 100-fold less potent than MVC at inhibiting HIV entry and replication (Fig. 6) , thus strongly suggesting that the antiviral potency of both molecules does not rely only on their capacity to interfere with gp120 binding to the coreceptor. Our results are in keeping with previous data showing that anti-CCR5 mAbs that are poor inhibitors of gp120 binding to CCR5 inhibit very efficiently viral entry, and conversely (23, 66) . This is consistent with the view that gp120-coreceptor interactions and HIV entry and replication require different structural determinants and/or conformations of CCR5. Remarkably, a previous study has shown that the anti-CCR5 mAb PA14 and small molecule CCR5 inhibitors synergize in blocking HIV-1 entry, thus suggesting that these two types of molecules act at different stages of CCR5 usage (11) . Similarly, we propose that TAK779 and MVC, which were shown here to inhibit gp120 binding with roughly similar potencies, affect differentially distinct steps of CCR5 usage in the course of HIV-1 infection. This assumption is fully consistent with the previous observations that small molecule CCR5 inhibitors, as allosteric molecules, can alter differentially distinct functions of the receptor (18, 19, 21) . Hence, MVC might be more efficient than TAK779 at inhibiting events that precede gp120 binding, including the interactions between CD4 and CCR5 that have been suggested to play a key role in HIV entry into target cells (67) . In this regard, we previously demonstrated that TAK779 impairs CCR5-CD4 interactions (68) , thereby suggesting that this process, which might result from conformational changes of CCR5, contributes to the antiviral activity of this molecule. TAK779 and MVC might also act differentially at stages following gp120 attachment to CCR5, for example during recruitment of the coreceptor within a fusion complex or triggering of gp120/CCR5 conformational changes that are required for fusion, as was speculated regarding the mechanism of action of PA14 (11) . Finally, signaling downstream of CCR5, which has been speculated to influence post-entry events of the virus life cycle (62), might also be differentially affected by TAK779 and MVC. We believe that targeting these different stages of CCR5 usage might provide clues for improving the development of small molecule CCR5 inhibitors and their therapeutic usage.
